Aviceda Ophthalmics is a biotech company focused on the next generation of glyco-immune therapeutics (GIT's) leveraging the Glyco-Code^® technology platform to address inflammatory diseases of the innate immune system.

Disease driven by dysregulation of the innate immune-inflammatory response is frequently a result of the same chronically activated, non-resolving cellular and non-cellular innate immune pathways. By unraveling the universal functionality of the Glyco-Code® and accessing the corresponding glyco-immune checkpoints, Aviceda can address a wide range of ocular immune-inflammatory, degenerative, and fibrotic diseases with significant unmet medical needs.

At Aviceda Ophthalmics, we exploit a unique family of receptors found expressed on all innate immune cells and their associated glycobiological interactions to develop transformative medicines. Combining the power of our biology with our innovative cell-based high-throughput screening (HTS) platform and proprietary nanoparticle technology, we are able to modulate the innate immune response specifically and profoundly.

Aviceda Ophthalmics is developing a pipeline of GITs that are delivered via biodegradable nanoparticles and which safely and effectively target both cellular and humoral aspects of inflammatory processes in AMD; this work will lay the groundwork for future development of GITs targeting other immune-inflammatory conditions.

Aviceda Ophthalmics’ lead optimized candidate nanoparticle as an intravitreal formulation, AVD-104, is being developed to target various immune system responses that contribute to pathology associated with non-exudative (Dry) AMD. GITs are the only therapeutics platform that can target BOTH cellular and humoral (i.e, complement) aspects of innate immune response profoundly and specifically, which differentiates from previous strategies to attenuate immune responses in non-exudative (Dry) AMD that focused only on shutting down humoral components of the immune response.